Clinical trial is halted for lupus drug Riquent
Monitoring board: treatment 'futile'
Friday, February 13, 2009
Lupus patients across the nation were distraught by the news yesterday that La Jolla Pharmaceutical stopped the clinical trial of its drug Riquent.
An independent monitoring board looked at preliminary trial data and determined that using the drug was “futile” in stopping deadly symptoms of lupus, the company said in a one-paragraph news release.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms